First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)

High Frequency of Mutations of the <i>PIK3CA</i> Gene in Human Cancers

Yardena Samuels, Zhenghe Wang, Alberto Bardelli et al. · Science · 2004 · 3.4K citations

Medicine, Genetics, Oncology +11

mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in <i>PIK3CA</i> -Mutant Breast Cancer

Moshe Elkabets, Sadhna Vora, Dejan Juric et al. · Science Translational Medicine · 2013 · 347 citations · Full text

Medicine, Oncology, Pharmacology +17

Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors

Filip Jankú, David S. Hong, Siqing Fu et al. · Cell Reports · 2014 · 237 citations · Full text

Medicine, Oncology, Pharmacology +17

5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology

Florent Beaufils, Nataša Cmiljanović, Vladimir Cmiljanović et al. · Journal of Medicinal Chemistry · 2017 · 134 citations · Full text

Medicine, Oncology, Pharmacology +14

Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy

Cristina Saura, Johanna C. Bendell, Guy Jérusalem et al. · Clinical Cancer Research · 2014 · 134 citations · Full text

Medicine, Oncology, Pharmacology +17